Genetic cross-interaction between apoe and prnp in sporadic alzheimer's and creutzfeldt-jakob diseases

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Calero, Olga ^a,b   Bullido, María J ^a,c,d   Clarimón, Jordi ^a,e   Frank García, Ana ^a,d   Martínez Martín, Pablo ^a,f   Lleó, Alberto ^a,e   Rey, María Jesús ^g   Rábano, Alberto ^h   Blesa, Rafael ^a,e   Gómez Isla, Teresa ^a,e   Valdivieso, Fernando ^a,c,d   de Pedro Cuesta, Jesús ^a,f   Ferrer, Isidro ^a,i   Calero, Miguel ^a,b  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

^g UNIVERSITY OF BARCELONA   (Spain)

^h Instituto de Salud Carlos III   (Spain)

ⁱ HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; APOLIPOPROTEIN E; PRNP PROTEIN, HUMAN;

AGE; AGED; ALLELE; ALZHEIMER DISEASE; APOE GENE; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GENDER; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MARKER GENE; ONSET AGE; PRNP GENE; SPORADIC CREUTZFELDT JAKOB DISEASE; CASE CONTROL STUDY; CODON; CREUTZFELDT JAKOB DISEASE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; PRION;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; CODON; CREUTZFELDT-JAKOB SYNDROME; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; POLYMORPHISM, GENETIC; PRIONS;

EID: 79960629063     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022090     Document Type: Article

References (81)

1. Gambetti P, Russo C, (1998) Human brain amyloidoses. Nephrol Dial Transplant 13 (Suppl 7): 33-40.
2. Checler F, Vincent B, (2002) Alzheimer's and prion diseases: distinct pathologies, common proteolytic denominators. Trends Neurosci 25 (12): 616-620.
3. Aguzzi A, Haass C, (2003) Games played by rogue proteins in prion disorders and Alzheimer's disease. Science 302 (5646): 814-818.
4. Armstrong RA, Lantos PL, Cairns NJ, (2005) Overlap between neurodegenerative disorders. Neuropathology 25 (2): 111-124.
5. Barnham KJ, Cappai R, Beyreuther K, Masters CL, Hill AF, (2006) Delineating common molecular mechanisms in Alzheimer's and prion diseases. Trends Biochem Sci 31 (8): 465-472.
6. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (5123): 921-923.
7. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, et al. (1993) Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43 (8): 1467-1472.
8. Mead S, (2006) Prion disease genetics. Eur J Hum Genet 14 (3): 273-281.
9. Golanska E, Hulas-Bigoszewska K, Rutkiewicz E, Styczynska M, Peplonska B, et al. (2004) Polymorphisms within the prion (PrP) and prion-like protein (Doppel) genes in AD. Neurology 62 (2): 313-315.
10. Riemenschneider M, Klopp N, Xiang W, Wagenpfeil S, Vollmert C, et al. (2004) Prion protein codon 129 polymorphism and risk of Alzheimer disease. Neurology 63 (2): 364-366.
11. Gacia M, Safranow K, Styczyńska M, Jakubowska K, Pepłońska B, et al. (2006) Prion protein gene M129 allele is a risk factor for Alzheimer's disease. J Neural Transm 113 (11): 1747-1751.
12. Combarros O, Sánchez-Guerra M, Llorca J, Alvarez-Arcaya A, Berciano J, et al. (2000) Polymorphism at codon 129 of the prion protein gene is not associated with sporadic AD. Neurology 55 (4): 593-595.
13. Casadei VM, Ferri C, Calabrese E, Grimaldi LM, Franceschi M, et al. (2001) Prion protein gene polymorphism and Alzheimer's disease: one modulatory trait of cognitive decline? J Neurol Neurosurg Psychiatry 71 (2): 279-280.
14. Dermaut B, Croes EA, Rademakers R, Van den Broeck M, Cruts M, et al. (2003) PRNP Val129 homozygosity increases risk for early-onset Alzheimer's disease. Ann Neurol 53 (3): 409-412.
15. Li X, Rowland LP, Mitsumoto H, Przedborski S, Bird TD, et al. (2005) Prion protein codon 129 genotype prevalence is altered in primary progressive aphasia. Ann Neurol 58 (6): 858-864.
16. Del Bo R, Scarlato M, Ghezzi S, Martinelli-Boneschi F, Fenoglio C, et al. (2006) Is M129V of PRNP gene associated with Alzheimer's disease? A case-control study and a meta-analysis. Neurobiol Aging 27 (5): 770.e1-770.e5.
17. Poleggi A, Bizzarro A, Acciarri A, Antuono P, Bagnoli S, et al. (2008) Codon 129 polymorphism of prion protein gene in sporadic Alzheimer's disease. Eur J Neurol 15 (2): 173-178.
18. Cousin E, Macé S, Rocher C, Dib C, Muzard G, et al. (2009) No replication of genetic association between candidate polymorphisms and Alzheimer's disease. Neurobiol Aging 2009 Nov 2. [Epub ahead of print].
19. Schjeide BM, McQueen MB, Mullin K, DiVito J, Hogan MF, et al. (2009) Assessment of Alzheimer's disease case-control associations using family-based methods. Neurogenetics 10 (1): 19-25.
20. Amouyel P, Vidal O, Launay JM, Laplanche JL, (1994) The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt-Jakob disease. The French Research Group on Epidemiology of Human Spongiform Encephalopathies. Lancet 344 (8933): 1315-1318.
21. Van Everbroeck B, Croes EA, Pals P, Dermaut B, Jansen G, et al. (2001) Influence of the prion protein and the apolipoprotein E genotype on the Creutzfeldt-Jakob Disease phenotype. Neurosci Lett 313 (1-2): 69-72.
22. Saunders AM, Schmader K, Breitner JC, Benson MD, Brown WT, et al. (1993) Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet 342 (8873): 710-711.
23. Zerr I, Helmhold M, Armstrong VW, Weber T, (1995) Apolipoprotein E in Creutzfeldt-Jakob disease. Lancet 345 (8941): 68-69.
24. Salvatore M, Seeber AC, Nacmias B, Petraroli R, D'Alessandro M, et al. (1995) Apolipoprotein E in sporadic and familial Creutzfeldt-Jakob disease. Neurosci Lett 199 (2): 95-98.
25. Friedman G, Gabizon R, Ben-Yehuda A, (1997) Apolipoprotein Eepsilon4 allele, a risk factor for late onset nonfamilial Alzheimer's disease among Israeli Jews. Arch Gerontol Geriatr 24 (2): 175-181.
26. Zerr I, Helmhold M, Poser S, Armstrong VW, Weber T, (1996) Apolipoprotein E phenotype frequency and cerebrospinal fluid concentration are not associated with Creutzfeldt-Jakob disease. Arch Neurol 53 (12): 1233-1238.
27. Varges D, Jung K, Gawinecka J, Heinemann U, Schmitz M, et al. (2011) Amyloid-β 1-42 levels are modified by apolipoprotein E ε4 in Creutzfeldt-Jakob disease in a similar manner as in Alzheimer's disease. J Alzheimers Dis 23 (4): 717-726.
28. Chapman J, Korczyn AD, Karussis DM, Michaelson DM, (2001) The effects of APOE genotype on age at onset and progression of neurodegenerative diseases. Neurology 57 (8): 1482-1485.
29. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, et al. (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 7 (2): 180-184.
30. Pickering-Brown SM, Mann DM, Owen F, Ironside JW, de Silva R, (1995) Allelic variations in apolipoprotein E and prion protein genotype related to plaque formation and age of onset in sporadic Creutzfeldt-Jakob disease. Neurosci Lett 187 (2): 127-129.
31. Gambetti P, Kong Q, Zou W, Parchi P, Chen SG, (2003) Sporadic and familial CJD: classification and characterisation. Br Med Bull 66: 213-239.
32. Hill AF, Joiner S, Wadsworth JD, Sidle KC, Bell JE, et al. (2003) Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain 126 (Pt 6): 1333-1346.
33. Berr C, Richard F, Dufouil C, Amant C, Alperovitch A, et al. (1998) Polymorphism of the prion protein is associated with cognitive impairment in the elderly: the EVA study. Neurology 51 (3): 734-737.
34. Giannattasio C, Poleggi A, Puopolo M, Pocchiari M, Antuono P, et al. (2008) Survival in Alzheimer's disease is shorter in women carrying heterozygosity at codon 129 of the PRNP gene and no APOE epsilon 4 allele. Dement Geriatr Cogn Disord 25 (4): 354-358.
35. Parkin ET, Watt NT, Hussain I, Eckman EA, Eckman CB, (2007) Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc Natl Acad Sci U S A 104 (26): 11062-11067.
36. Kellett KA, Hooper NM, (2009) Prion protein and Alzheimer disease. Prion 3 (4): 190-194.
37. Nygaard HB, Strittmatter SM, (2009) Cellular prion protein mediates the toxicity of beta-amyloid oligomers: implications for Alzheimer disease. Arch Neurol 66 (11): 1325-1328.
38. Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM, (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457 (7233): 1128-1132.
39. Gunther EC, Strittmatter SM, (2010) Beta-amyloid oligomers and cellular prion protein in Alzheimer's disease. J Mol Med 88 (4): 331-338.
40. Chung E, Ji Y, Sun Y, Kascsak RJ, Kascsak RB, et al. (2010) Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. BMC Neurosci 11: 130.
41. Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Laurén J, et al. (2010) Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci 5;30 (18): 6367-6374.
42. Price DL, Borchelt DR, Sisodia SS, (1993) Alzheimer disease and the prion disorders amyloid beta-protein and prion protein amyloidoses. Proc Natl Acad Sci U S A 90 (14): 6381-6384.
43. de Pedro-Cuesta J, Mahillo-Fernandez I, Rabano A, Calero M, Cruz M, et al. (2011) Nosocomial transmission of sporadic Creutzfeldt-Jakob disease: results from a risk-based assessment of surgical interventions. J Neurol Neurosurg Psychiatry 82 (2): 204-212.
44. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE, (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39 (1): 17-23.
45. Combarros O, Cortina-Borja M, Smith AD, Lehmann DJ, (2009) Epistasis in sporadic Alzheimer's disease. Neurobiol Aging 30 (9): 1333-1349.
46. Schmidt C, Redyk K, Meissner B, Krack L, von Ahsen N, et al. (2010) Clinical features of rapidly progressive Alzheimer's disease. Dement Geriatr Cogn Disord 29 (4): 371-378.
47. Debatin L, Streffer J, Geissen M, Matschke J, Aguzzi A, et al. (2008) Association between deposition of beta-amyloid and pathological prion protein in sporadic Creutzfeldt-Jakob disease. Neurodegener Dis 5 (6): 347-354.
48. Hainfellner JA, Wanschitz J, Jellinger K, Liberski PP, Gullotta F, et al. (1998) Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol 96 (2): 116-122.
49. Ferrer I, Blanco R, Carmona M, Puig B, Ribera R, et al. (2001) Prion protein expression in senile plaques in Alzheimer's disease. Acta Neuropathol 101 (1): 49-56.
50. Voigtländer T, Klöppel S, Birner P, Jarius C, Flicker H, et al. (2001) Marked increase of neuronal prion protein immunoreactivity in Alzheimer's disease and human prion diseases. Acta Neuropathol 101 (5): 417-423.
51. Kovacs GG, Zerbi P, Voigtländer T, Strohschneider M, Trabattoni G, et al. (2002) The prion protein in human neurodegenerative disorders. Neurosci Lett 329 (3): 269-272.
52. Takahashi RH, Tobiume M, Sato Y, Sata T, Gouras GK, et al. (2010) Accumulation of cellular prion protein within dystrophic neurites of amyloid plaques in the Alzheimer's disease brain. Neuropathology 2010 Nov 9 [Epub ahead of print].
53. Morales R, Estrada LD, Diaz-Espinoza R, Morales-Scheihing D, Jara MC, et al. (2010) Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases. J Neurosci 30 (13): 4528-4535.
54. Rushworth JV, Hooper NM, (2010) Lipid Rafts: Linking Alzheimer's Amyloid-β Production, Aggregation, and Toxicity at Neuronal Membranes. Int J Alzheimers Dis 2010 Dec 27.
55. Cerf E, Gustot A, Goormaghtigh E, Ruysschaert J.-M, Raussens V, (2011) High ability of apolipoprotein E4 to stabilize amyloid-β peptide oligomers, the pathological entities responsible for Alzheimer's disease. FASEB J 2011 Jan 25. [Epub ahead of print].
56. Kim J, Basak JM, Holtzman DM, (2009) The role of apolipoprotein E in Alzheimer's disease. Neuron 63 (3): 287-303.
57. Bu G, (2009) Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 10 (5): 333-44.
58. Sharman MJ, Morici M, Hone E, Berger T, Taddei K, et al. (2010) APOE genotype results in differential effects on the peripheral clearance of amyloid-beta42 in APOE knock-in and knock-out mice. J Alzheimers Dis 21 (2): 403-409.
59. Petrlova J, Hong HS, Bricarello DA, Harishchandra G, Lorigan GA, et al. (2011) A differential association of Apolipoprotein E isoforms with the amyloid-β oligomer in solution. Proteins 79 (2): 402-416.
60. Hoe HS, Harris DC, Rebeck GW, (2005) Multiple pathways of apolipoprotein E signaling in primary neurons. J Neurochem 93 (1): 145-55.
61. Kim D, Tsai LH, (2009) Bridging physiology and pathology in AD. Cell 137 (6): 997-1000.
62. Palmer MS, Dryden AJ, Hughes JT, Collinge J, (1991) Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature 352 (6333): 340-342.
63. Chiesa R, Piccardo P, Biasini E, Ghetti B, Harris DA, (2008) Aggregated, wild-type prion protein causes neurological dysfunction and synaptic abnormalities. J Neurosci 28 (49): 13258-13267.
64. Minaki H, Sasaki K, Honda H, Iwaki T, (2009) Prion protein oligomers in Creutzfeldt-Jakob disease detected by gel-filtration centrifuge columns. Neuropathology 29 (5): 536-542.
65. Gavín R, Ureña J, Rangel A, Pastrana MA, Requena JR, et al. (2008) Fibrillar prion peptide PrP(106-126) treatment induces Dab1 phosphorylation and impairs APP processing and Abeta production in cortical neurons. Neurobiol Dis 30 (2): 243-254.
66. Gavín R, Ferrer I, del Río JA, (2010) Involvement of Dab1 in APP processing and beta-amyloid deposition in sporadic Creutzfeldt-Jakob patients. Neurobiol Dis 37 (2): 324-329.
67. Kesäniemi YA, Ehnholm C, Miettinen TA, (1987) Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. J Clin Invest 80 (2): 578-581.
68. Mahley RW, Huang Y, (1999) Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol 10 (3): 207-217.
69. Gilch S, Kehler C, Schätzl HM, (2006) The prion protein requires cholesterol for cell surface localization. Mol Cell Neurosci 31 (2): 346-353.
70. Huang Y, (2010) Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. Trends Mol Med 16 (6): 287-294.
71. Mead S, Stumpf MP, Whitfield J, Beck JA, Poulter M, et al. (2003) Balancing selection at the prion protein gene consistent with prehistoric kurulike epidemics. Science 300 (5619): 640-643.
72. Eisenberg DT, Kuzawa CW, Hayes MG, (2010) Worldwide allele frequencies of the human apolipoprotein E gene: climate, local adaptations, and evolutionary history. Am J Phys Anthropol 143 (1): 100-111.
73. Soldevila M, Andrés AM, Ramírez-Soriano A, Marquès-Bonet T, Calafell F, et al. (2006) The prion protein gene in humans revisited: lessons from a worldwide resequencing study. Genome Res 16 (2): 231-239.
74. Wade MJ, (2001) Epistasis, complex traits, and mapping genes. Genetica 112-113: 59-69.
75. Moore JH, Williams SM, (2005) Traversing the conceptual divide between biological and statistical epistasis: systems biology and a more modern synthesis. Bioessays 27 (6): 637-646.
76. Golanska E, Hulas-Bigoszewska K, Sieruta M, Zawlik I, Witusik M, et al. (2009) Earlier onset of Alzheimer's disease: risk polymorphisms within PRNP, PRND, CYP46, and APOE genes. J Alzheimers Dis 17 (2): 359-368.
77. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (7): 939-944.
78. Calero O, Hortigüela R, Bullido MJ, Calero M, (2009) Apolipoprotein E genotyping method by real time PCR, a fast and cost-effective alternative to the TaqMan and FRET assays. J Neurosci Methods 183 (2): 238-240.
79. Martínez-García A, Sastre I, Tenorio R, Bullido MJ, (2004) SNP genotyping with FRET probes. Optimizing the resolution of heterozygotes. Mol Cell Probes 18: 211-214.
80. Calero O, Hortigüela R, Albo C, de Pedro-Cuesta J, Calero M, (2009) Allelic discrimination of genetic human prion diseases by real-time PCR genotyping. Prion 3 (3): 146-150.
81. Cortina-Borja M, Smith AD, Combarros O, Lehmann DJ, (2009) The synergy factor: a statistic to measure interactions in complex diseases. BMC Res Notes 2: 105.